Back

In situ evidence that mast cells release mutant NLRP1 in keratoacanthomas from multiple self-healing palmoplantar carcinoma

Dobre, A.; Fertig, T. E.; Niculae, A. M.; Cohn, A. M.; Curici, A.; Andrei, R. T.; Marta, D. S.; Peteu, V. E.; Popescu, R. G.; Marinescu, G. C.; Turcu, G.; Forsea, A. M.; Ion, D. A.; Gherghiceanu, M.; Nedelcu, R. I.

2025-09-17 immunology
10.1101/2025.09.12.675637 bioRxiv
Show abstract

NLRP1 is an inflammasome sensor protein expressed in barrier tissues of humans. Its activation in response to microbes or cellular stress triggers a cascade of molecular events, leading up to IL1{beta}-driven inflammation and pyroptosis. Rare germline mutations of NLRP1 cause its persistent activation, resulting in autoinflammatory syndromes. Multiple self-healing palmoplantar carcinoma (MSPC) is one such syndrome, characterized by the appearance of recurrent keratoacanthomas (KAs) on the palms and soles. Here, we aimed to compare the subcellular localization of mutant NLRP1 in MSPC-associated lesions, to wild-type NLRP1 in non-MSPC KAs and in skin from healthy donors. Using mass spectrometry, immunohistochemistry and immunoelectron tomography, we found that NLRP1 localized to mast cell (MC) granules in all samples, a novel finding which implicates MCs in NLRP1-associated responses in human skin. Moreover, we found that MCs expressing the A66V pathogenic variant of NLRP1 overpopulated MSPC-KAs, infiltrated the epidermis and degranulated, a behavior not seen in other lesions from this study. The released granules had the highest NLRP1 protein content and also contained NLRP3 and IL1{beta}, indicating coexistence of inflammasome pathways within MCs. Taken together, our findings establish cutaneous MCs as a NLRP1 reservoir in health and disease, opening a new area of research in NLRP1-related syndromes.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Journal of Investigative Dermatology
42 papers in training set
Top 0.1%
39.4%
2
Frontiers in Immunology
586 papers in training set
Top 1%
6.6%
3
Nature Communications
4913 papers in training set
Top 34%
4.5%
50% of probability mass above
4
Allergy
23 papers in training set
Top 0.1%
4.1%
5
Journal of Allergy and Clinical Immunology
25 papers in training set
Top 0.2%
3.7%
6
Scientific Reports
3102 papers in training set
Top 43%
2.8%
7
Journal of Experimental Medicine
106 papers in training set
Top 1%
2.2%
8
eLife
5422 papers in training set
Top 34%
2.2%
9
Matrix Biology
28 papers in training set
Top 0.2%
1.4%
10
The Journal of Pathology
22 papers in training set
Top 0.2%
1.4%
11
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.3%
12
European Journal of Immunology
57 papers in training set
Top 0.3%
1.3%
13
Arthritis & Rheumatology
33 papers in training set
Top 0.4%
1.0%
14
JCI Insight
241 papers in training set
Top 6%
0.9%
15
Annals of the Rheumatic Diseases
32 papers in training set
Top 0.6%
0.8%
16
Advanced Science
249 papers in training set
Top 18%
0.8%
17
iScience
1063 papers in training set
Top 32%
0.7%
18
npj Genomic Medicine
33 papers in training set
Top 1%
0.7%
19
Science Immunology
81 papers in training set
Top 2%
0.7%
20
Cell Reports
1338 papers in training set
Top 35%
0.7%
21
Open Biology
95 papers in training set
Top 3%
0.7%
22
EMBO Molecular Medicine
85 papers in training set
Top 5%
0.7%
23
Signal Transduction and Targeted Therapy
29 papers in training set
Top 2%
0.7%
24
Experimental Dermatology
10 papers in training set
Top 0.3%
0.5%
25
Cell Reports Medicine
140 papers in training set
Top 10%
0.5%
26
Theranostics
33 papers in training set
Top 2%
0.5%
27
Immunology
29 papers in training set
Top 1%
0.5%